Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life

Kidney International

Volumn 79, Issue 6, 2011, Pages 678-685

  Gipson, Debbie S ^a   Trachtman, Howard ^b   Kaskel, Frederick J ^c   Radeva, Milena K ^d   Gassman, Jennifer ^d   Greene, Tom H ^e   Moxey Mims, Marva M ^f   Hogg, Ronald J ^g   Watkins, Sandra L ^h   Fine, Richard N ⁱ   Middleton, John P ^j   Vehaskari, V M ^k   Hogan, Susan L ^l   Vento, Suzzane ^b   Flynn, Patti A ^c   Powell, Leslie M ^l   McMahan, June L ^d   Siegel, Norman ⁿ   Friedman, Aaron L ^m  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Oncology and Cellular Therapy   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁿ NONE

more..

Author keywords

focal segmental glomerulosclerosis; proteinuria; quality of life; randomized controlled trial

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CHILD; DRUG EFFICACY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 79952186177     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.485     Document Type: Article

References (39)

1. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2: 529-542.
2. Barisoni L, Schnaper HW, Kopp JB. Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med 2009; 133: 201-216.
3. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 2003; 23: 147-160. (Pubitemid 36397097)
4. Chun MJ, Korbet SM, Schwartz MM et al. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15: 2169-2177. (Pubitemid 39031355)
5. Thomas DB, Franceschini N, Hogan SL et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69: 920-926.
6. Rydel JJ, Korbet SM, Borok RZ et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995; 25: 534-542.
7. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 2008; (3): CD003233.
8. Abrantes MM, Cardoso LSB, Lima EM et al. Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis. Pediatr Nephrol 2006; 21: 1003-1012. (Pubitemid 43885101)
9. Moranne O, Watier L, Rossert J et al. Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM 2008; 101: 215-224. (Pubitemid 351315011)
10. Alexopoulos E, Stangou M, Papagianni A et al. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15: 1348-1356.
11. Bakir AA, Share DS, Levy PS et al. Focal segmental glomerulosclerosis in adult African Americans. Clin Nephrol 1996; 46: 306-311. (Pubitemid 26390753)
12. Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother 2009; 10: 615-628.
13. Fernandez-Fresnedo G, Segarra A, Gonzalez E et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4: 1317-1323.
14. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56: 2220-2226. (Pubitemid 30004751)
15. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7: 56-63. (Pubitemid 26068448)
16. Smith D, Branton M, Fervenza F et al. Pulse dexamethasone for focal segmental glomerulosclerosis. J Am Soc Nephrol 2003; 13: 526a.
17. Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8: 824-832. (Pubitemid 27493599)
18. Nayagam LS, Ganguli A, Rathi M et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23: 1926-1930. (Pubitemid 351768140)
19. Cattran DC, Wang MM, Appel G et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62: 405-411. (Pubitemid 39654577)
20. Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes 2007; 5: 43.
21. Goldstein SL, Graham N, Warady BA et al. Measuring health-related quality of life in children with ESRD: performance of the generic and ESRD-specific instrument of the Pediatric Quality of Life Inventory (PedsQL). Am J Kidney Dis 2008; 51: 285-297.
22. Unruh M, Benz R, Greene T et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 2004; 66: 355-366. (Pubitemid 38870113)
23. Ware J, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Quality Metric Incorporated: Lincoln, RI, 2003.
24. Dragovic D, Rosenstock JL, Wahl SJ et al. Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol 2005; 63: 1-7. (Pubitemid 40109612)
25. Boyer O, Moulder JK, Somers MJG. Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol 2007; 22: 1159-1166.
26. Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005; 20: 707-711. (Pubitemid 40520646)
27. Mapes DL, Bragg-Gresham JL, Bommer J et al. Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 54-60.
28. Gerson AC, Wentz A, Abraham AG et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics 2010; 125: 349-357.
29. Han SS, Kim KW, Na KY et al. Quality of life and mortality from a nephrologist's view: a prospective observational study. BMC Nephrol 2009; 10: 39.
30. Rizk D, Jurkovitz C, Veledar E et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 2009; 4: 560-566.
31. Ruth E-M, Landolt MA, Neuhaus TJ et al. Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr 2004; 145: 778-783. (Pubitemid 39586616)
32. Paniagua R, Amato D, Vonesh E et al. Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: the ADEMEX trial. Kidney Int 2005; 67: 1093-1104. (Pubitemid 41623335)
33. Mujais SK, Story K, Brouillette J et al. Health-related quality of life in CKD patients: correlates and evolution over time. Clin J Am Soc Nephrol 2009; 4: 1293-1301.
34. Winn MP. Not all in the family: mutations of podocin in sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13: 577-579. (Pubitemid 34106303)
35. D'Agati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43: 368-382. (Pubitemid 38146337)
36. Schwartz GJ, Haycock GB, Edelmann CM et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263.
37. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
38. Meyer KB, Espindle DM, DeGiacomo JM et al. Monitoring dialysis patients' health status. Am J Kidney Dis 1994; 24: 267-279. (Pubitemid 24249067)
39. Kurtin PS, Davies AR, Meyer KB et al. Patient-based health status measures in outpatient dialysis. Early experiences in developing an outcomes assessment program. Med Care 1992; 30: 136-149.